40 completed. 40 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 40 | Completed 40 |
| Phase 2 | 12 | Completed 12 |
Follow Refractory Multiple Myeloma: new trials by email Literature Review of Refractory Multiple Myeloma trials Research Report on Refractory Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cyclophosphamide - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Completed | Elvira Umyarova | 3 | 2024-03-05 | 2026-07-01 |
| A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma ION251 - Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Completed | Ionis Pharmaceuticals, Inc. | 23 | 2021-01-20 | 2024-10-31 |
| A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma RO7297089 - Refractory Multiple Myeloma, Relapsed Multiple Myeloma | Phase 1 | Completed | Genentech, Inc. | 27 | 2020-07-08 | 2024-07-03 |
| Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment Ixazomib Citrate, Pevonedistat - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Completed | National Cancer Institute (NCI) | 8 | 2020-02-10 | 2025-06-19 |
| First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) REGN5459 - Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Completed | Regeneron Pharmaceuticals | 43 | 2019-09-26 | 2026-05-04 |
| Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma Ibrutinib, Lenalidomide, Dexamethasone - Refractory Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 | Completed | Alliance Foundation Trials, LLC. | 14 | 2019-08-29 | 2026-01-06 |
| Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis - Anemia, Recurrent Multiple Myeloma | Phase 1 | Completed | National Cancer Institute (NCI) | 12 | 2014-12-09 | 2024-05-17 |
| Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma selinexor, carfilzomib, dexamethasone - Refractory Multiple Myeloma | Phase 1 | Completed | University of Chicago | 52 | 2014-06-12 | 2025-11-03 |
| Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma pomalidomide, marizomib, low-dose dexamethasone - Multiple Myeloma in Relapse, Refractory Multiple Myeloma | Phase 1 | Completed | Celgene | 38 | 2014-06-05 | 2017-11-22 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma pomalidomide, bortezomib, dexamethasone - Refractory Multiple Myeloma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 50 | 2011-09-01 | 2020-04-17 |
| Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies fludarabine phosphate, methoxyamine, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Case Comprehensive Cancer Center | 20 | 2011-05-01 | 2015-08-13 |
| Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia MLN0128 - Relapsed Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 39 | 2010-11-01 | 2013-08-02 |
| Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma azacitidine, lenalidomide, dexamethasone - Refractory Multiple Myeloma | Phase 1 / Phase 2 | Completed | Case Comprehensive Cancer Center | 45 | 2010-06-01 | 2020-11-16 |
| AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma Pharmacodynamic Studies, Fatigue Inventory, Pharmacogenomic studies - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Amir Mortazavi | 44 | 2010-05-04 | 2018-06-04 |
| Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma plerixafor, filgrastim, cyclophosphamide - Refractory Multiple Myeloma, Stage I Multiple Myeloma | Phase 1 | Completed | City of Hope Medical Center | 18 | 2010-04-01 | 2013-02-15 |
| Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma bendamustine hydrochloride, lenalidomide, dexamethasone - Refractory Multiple Myeloma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 70 | 2010-02-01 | 2020-02-11 |
| Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma Aurora A kinase inhibitor MLN8237, bortezomib - Refractory Multiple Myeloma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 26 | 2010-02-01 | 2016-05-25 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy sunitinib malate, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2009-08-01 | 2014-03-17 |
| Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma panobinostat, everolimus, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 124 | 2009-06-01 | 2020-03-10 |
Showing 20 of 40. Sign in to see all of them.
Multiple Myeloma (40) · Leukemia, Lymphocytic, Chronic, B-Cell (14) · Burkitt Lymphoma (13) · Lymphoma, Follicular (13) · Lymphoma, Large B-Cell, Diffuse (13) · Lymphoma, Mantle-Cell (13) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (13) · Lymphoma, B-Cell, Marginal Zone (11) · Lymphoma, Large-Cell, Immunoblastic (11) · Lymphoma, Non-Hodgkin (11) · Waldenstrom Macroglobulinemia (11) · Hodgkin Disease (9) · Lymphoma, Extranodal NK-T-Cell (9) · Lymphoma, Large-Cell, Anaplastic (9) · Lymphoma, T-Cell, Cutaneous (8)
Blood Protein Disorders (40) · Cardiovascular Diseases (40) · Hematologic Diseases (40) · Hemic and Lymphatic Diseases (40) · Hemorrhagic Disorders (40) · Hemostatic Disorders (40) · Immune System Diseases (40) · Immunoproliferative Disorders (40) · Lymphoproliferative Disorders (40) · Neoplasms by Histologic Type (40) · Paraproteinemias (40) · Vascular Diseases (40) · Neoplasms (39) · Neoplasms, Plasma Cell (37) · Disease Attributes (16)
Dexamethasone (9) · Calcium Dobesilate (8) · Lenalidomide (7) · Bortezomib (6) · Cyclosporine (5) · Mycophenolic Acid (5) · Peripheral Blood Stem Cell Transplantation (5) · fludarabine phosphate (5) · Cyclophosphamide (4) · Whole-Body Irradiation (4) · Melphalan (3) · Biopsy (2) · Filgrastim (2) · Gene Expression Profiling (2) · Granulocyte Colony-Stimulating Factor (2)
National Cancer Institute (NCI) (14) · Fred Hutchinson Cancer Center (5) · Mayo Clinic (4) · City of Hope Medical Center (3) · Case Comprehensive Cancer Center (2) · Alliance Foundation Trials, LLC. (1) · Amir Mortazavi (1) · Celgene (1) · Dana-Farber Cancer Institute (1) · Elvira Umyarova (1) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1) · Genentech, Inc. (1) · Ionis Pharmaceuticals, Inc. (1) · Millennium Pharmaceuticals, Inc. (1) · Regeneron Pharmaceuticals (1)
United States (38) · Italy (4) · Australia (2) · Germany (2) · Belgium (1) · Denmark (1) · Norway (1)
David Maloney (3) · Shaji K. Kumar, M.D. (2) · Shaji Kumar (2) · Vivek Roy, M.D. (2) · Alan Lichtenstein (1) · Alexander K. Stewart, M.D. (1) · Amir Mortazavi, MD (1) · Amrita Krishnan (1) · Andrzej Jakubowiak (1) · Antonius Miller (1) · Ashraf Badros (1) · Brenda Cooper (1) · Brenda Sandmaier (1) · Charles Erlichman (1)
PMID 32499241, PMID 18974373, PMID 19182205, PMID 22259028, PMID 23887852, PMID 24474568, PMID 26331432, PMID 26853648, PMID 26943915, PMID 28270022, PMID 28684537, PMID 30562587, PMID 31124580, PMID 33476575, PMID 33492438, PMID 36656461, PMID 39828738
P30CA015704 (3), U01CA062502 (3), U01CA062505 (3), P01CA078902 (2), P30CA016058 (2), U01CA062487 (2), U01CA062491 (2), U01CA069912 (2), U01CA076576 (2), U01CA099168 (2), UM1CA186691 (2), 2019 (1), N01CM62204 (1), P01CA018029 (1), P30CA014599 (1)